Wed, Nov 27, 2024
[Archive]
Volume 3, Issue 1 (Feb 2018)
JNFS 2018, 3(1): 40-50 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Poursoleiman F, Mozaffari-Khosravi H, Naghdipour Biregani A. Does Omega-3 Fatty Acid Supplementation Have Beneficial Effects on Plasma Homocysteine, Insulin Resistance and Lipid Profile of Type 2 Diabetic Patients? A Randomized Clinical Trial. JNFS 2018; 3 (1) :40-50
URL: http://jnfs.ssu.ac.ir/article-1-127-en.html
URL: http://jnfs.ssu.ac.ir/article-1-127-en.html
Does Omega-3 Fatty Acid Supplementation Have Beneficial Effects on Plasma Homocysteine, Insulin Resistance and Lipid Profile of Type 2 Diabetic Patients? A Randomized Clinical Trial
Abstract: (3459 Views)
Background: This study was conducted to determine the effects of n-3 PUFAs supplementation on plasma homocysteine (Hcy) level, lipid profile and insulin resistance in patients with type 2 diabetes (T2D). Methods: This study is a double-blind controlled trial involving 70 patients with T2D selected from Yazd Diabetes Research Center in 2013. Patients were randomly assigned to receive either 2 g/day omega-3 soft gels (OG) or 2 g/day placebo (PG) for 6 weeks. At the beginning and end of the study, Hcy concentration, fasting plasma glucose (FBG), fasting plasma insulin, total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c), HDL-c/LDL-c ratio, insulin resistance (HOMA-IR), insulin sensitivity (IS) and beta-cell function were measured and compared. Results: Sixty five participants completed the study. The results of this study showed that
omega-3 fatty acid supplementation caused significant increase in Hcy
(P = 0.007) and LDLc (P = 0.02), while HDLc and HDLc/LDLc ratio were significantly decreased (P = 0.001 and 0.006, respectively). In both groups, insulin and HOMA-IR were increased, while IS decreased significantly. Βeta-cell function was increased only in OG (P = 0.005). There was no significant difference in mean change of any factors. Conclusion: The present study found no beneficial effects of 2 g/day omega-3 supplement for 6 weeks on biomarkers of Hcy, FBG, insulin and lipid profile in th T2D patients.
omega-3 fatty acid supplementation caused significant increase in Hcy
(P = 0.007) and LDLc (P = 0.02), while HDLc and HDLc/LDLc ratio were significantly decreased (P = 0.001 and 0.006, respectively). In both groups, insulin and HOMA-IR were increased, while IS decreased significantly. Βeta-cell function was increased only in OG (P = 0.005). There was no significant difference in mean change of any factors. Conclusion: The present study found no beneficial effects of 2 g/day omega-3 supplement for 6 weeks on biomarkers of Hcy, FBG, insulin and lipid profile in th T2D patients.
Type of article: orginal article |
Subject:
public specific
Received: 2017/04/15 | Published: 2018/01/30 | ePublished: 2018/01/30
Received: 2017/04/15 | Published: 2018/01/30 | ePublished: 2018/01/30
References
1. Benito P, et al. 2006. Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome. Clinical nutrition. 25 (4): 581-587.
2. Buse JB, et al. 2007. Primary prevention of cardiovascular diseases in people with diabetes mellitus a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes care. 30 (1): 162-172.
3. Chicco A, D’Alessandro M, Karabatas L, Gutman R & Lombardo Y 1996. Effect of moderate levels of dietary fish oil on insulin secretion and sensitivity, and pancreas insulin content in normal rats. Annals of nutrition and metabolism. 40 (2): 61-70.
4. Crochemore ICC, Souza AF, de Souza AC & Rosado EL 2012. ω-3 Polyunsaturated fatty acid supplementation does not influence body composition, insulin resistance, and lipemia in women with type 2 diabetes and obesity. Nutrition in clinical practice. 27 (4): 553-560.
5. D’Alessandro M, Lombardo Y & Chicco A 2002. Effect of dietary fish oil on insulin sensitivity and metabolic fate of glucose in the skeletal muscle of normal rats. Annals of nutrition and metabolism. 46 (3-4): 114-120.
6. Danaei G, et al. 2011. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2• 7 million participants. The lancet. 378 (9785): 31-40.
7. De Caterina R, Madonna R, Bertolotto A & Schmidt EB 2007. n-3 Fatty Acids in the Treatment of Diabetic Patients Biological rationale and clinical data. Diabetes care. 30 (4): 1012-1026.
8. Delarue J, LeFoll C, Corporeau C & Lucas D 2004. N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Reproduction nutrition development. 44 (3): 289-299.
9. Elias AN & Eng S 2005. Homocysteine concentrations in patients with diabetes mellitus–relationship to microvascular and macrovascular. Diabetes, obesity and metabolism. 7: 117-121.
10. Fiedler R, Mall M, Wand C & Osten B 2005. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. Journal of renal nutrition. 15 (2): 253-256.
11. Friday KE, et al. 1989. Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes. Diabetes care. 12 (4): 276-281.
12. García-Alonso F, Jorge-Vidal V, Ros G & Periago M 2012. Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women. European journal of nutrition. 51 (4): 415-424.
13. Giacco R, et al. 2007. Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: Is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of omega-6 and omega-3 fatty acids? Nutrition, metabolism and cardiovascular diseases. 17 (8): 572-580.
14. Grimsgaard S, Bonaa KH, Hansen J-B & Nordøy A 1997. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. The American journal of clinical nutrition. 66 (3): 649-659.
15. Grundt H, Nilsen DW, Mansoor MA, Hetland Ø & Nordøy A 2003. Reduction in homocysteine by n–3 polyunsaturated fatty acids after 1 year in a randomised double-blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. Pathophysiology of haemostasis and thrombosis. 33 (2): 88-95.
16. Haglund O, Hamfelt A, Hambraeus L & Saldeen T 1993. Effects of fish oil supplemented with pyridoxine and folic acid on homocysteine, atherogenic index, fibrinogen and plasminogen activator inhibitor-1 in man. Nutrition research. 13 (12): 1351-1365.
17. Hartweg J, Farmer A, Holman R & Neil H 2007. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia. 50 (2): 250-258.
18. Hofmann MA, et al. 2001. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. The journal of clinical investigation. 107 (6): 675-683.
19. Holness MJ GG, Smith ND, Sugden MC 2003. Diabetogenic Impact of Long-Chain ω-3 Fatty Acids on Pancreatic β-Cell Function and the Regulation of Endogenous Glucose Production. Endocrinology. 144 (9): 3958-3968.
20. House AA, et al. 2010. Effect of B-vitamin therapy on progression of diabetic nephropathy. The journal of the American medical asociation. 303 (16): 1603-1609.
21. Huang T, Asimi S, Lou D & Li D 2012. Plasma phospholipid polyunsaturated fatty acids and homocysteine in Chinese type 2 diabetes patients. Asia Pacific journal of clinical nutrition. 21 (3): 394.
22. Huang T, et al. 2011. High consumption of Ω-3 polyunsaturated fatty acids decrease plasma homocysteine: a meta-analysis of randomized, placebo-controlled trials. Nutrition. 27 (9): 863-867.
23. Kaushik M, et al. 2009. Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. The American journal of clinical nutrition. 90: 613-620.
24. Kris-Etherton PM, Harris WS & Appel LJ 2003. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology. 23 (2): e20-e30.
25. Lee D-H, et al. 2006. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes results from the National Health and Examination Survey 1999–2002. Diabetes care. 29 (7): 1638-1644.
26. Li D, et al. 2007. Platelet phospholipid omega−3 PUFA negatively associated with plasma homocysteine in middle-aged and geriatric hyperlipaemia patients. Prostaglandins, leukotrienes and essential fatty acids. 76 (5): 293-297.
27. Benito P, et al. 2006. Effects of milk enriched with omega-3 fatty acid, oleic acid and folic acid in patients with metabolic syndrome. Clinical nutrition. 25 (4): 581-587.
28. Buse JB, et al. 2007. Primary prevention of cardiovascular diseases in people with diabetes mellitus a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes care. 30 (1): 162-172.
29. Chicco A, D’Alessandro M, Karabatas L, Gutman R & Lombardo Y 1996. Effect of moderate levels of dietary fish oil on insulin secretion and sensitivity, and pancreas insulin content in normal rats. Annals of nutrition and metabolism. 40 (2): 61-70.
30. Crochemore ICC, Souza AF, de Souza AC & Rosado EL 2012. ω-3 Polyunsaturated fatty acid supplementation does not influence body composition, insulin resistance, and lipemia in women with type 2 diabetes and obesity. Nutrition in clinical practice. 27 (4): 553-560.
31. D’Alessandro M, Lombardo Y & Chicco A 2002. Effect of dietary fish oil on insulin sensitivity and metabolic fate of glucose in the skeletal muscle of normal rats. Annals of nutrition and metabolism. 46 (3-4): 114-120.
32. Danaei G, et al. 2011. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2• 7 million participants. The lancet. 378 (9785): 31-40.
33. De Caterina R, Madonna R, Bertolotto A & Schmidt EB 2007. n-3 Fatty Acids in the Treatment of Diabetic Patients Biological rationale and clinical data. Diabetes care. 30 (4): 1012-1026.
34. Delarue J, LeFoll C, Corporeau C & Lucas D 2004. N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Reproduction nutrition development. 44 (3): 289-299.
35. Elias AN & Eng S 2005. Homocysteine concentrations in patients with diabetes mellitus–relationship to microvascular and macrovascular. Diabetes, obesity and metabolism. 7: 117-121.
36. Fiedler R, Mall M, Wand C & Osten B 2005. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. Journal of renal nutrition. 15 (2): 253-256.
37. Friday KE, et al. 1989. Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes. Diabetes care. 12 (4): 276-281.
38. García-Alonso F, Jorge-Vidal V, Ros G & Periago M 2012. Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women. European journal of nutrition. 51 (4): 415-424.
39. Giacco R, et al. 2007. Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: Is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of omega-6 and omega-3 fatty acids? Nutrition, metabolism and cardiovascular diseases. 17 (8): 572-580.
40. Grimsgaard S, Bonaa KH, Hansen J-B & Nordøy A 1997. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. The American journal of clinical nutrition. 66 (3): 649-659.
41. Grundt H, Nilsen DW, Mansoor MA, Hetland Ø & Nordøy A 2003. Reduction in homocysteine by n–3 polyunsaturated fatty acids after 1 year in a randomised double-blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. Pathophysiology of haemostasis and thrombosis. 33 (2): 88-95.
42. Haglund O, Hamfelt A, Hambraeus L & Saldeen T 1993. Effects of fish oil supplemented with pyridoxine and folic acid on homocysteine, atherogenic index, fibrinogen and plasminogen activator inhibitor-1 in man. Nutrition research. 13 (12): 1351-1365.
43. Hartweg J, Farmer A, Holman R & Neil H 2007. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia. 50 (2): 250-258.
44. Hofmann MA, et al. 2001. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. The journal of clinical investigation. 107 (6): 675-683.
45. Holness MJ GG, Smith ND, Sugden MC 2003. Diabetogenic Impact of Long-Chain ω-3 Fatty Acids on Pancreatic β-Cell Function and the Regulation of Endogenous Glucose Production. Endocrinology. 144 (9): 3958-3968.
46. House AA, et al. 2010. Effect of B-vitamin therapy on progression of diabetic nephropathy. The journal of the American medical asociation. 303 (16): 1603-1609.
47. Huang T, Asimi S, Lou D & Li D 2012. Plasma phospholipid polyunsaturated fatty acids and homocysteine in Chinese type 2 diabetes patients. Asia Pacific journal of clinical nutrition. 21 (3): 394.
48. Huang T, et al. 2011. High consumption of Ω-3 polyunsaturated fatty acids decrease plasma homocysteine: a meta-analysis of randomized, placebo-controlled trials. Nutrition. 27 (9): 863-867.
49. Kaushik M, et al. 2009. Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. The American journal of clinical nutrition. 90: 613-620.
50. Kris-Etherton PM, Harris WS & AppelLJ 2003. Fish consumption, fish oil,omega-3 fatty acids, and cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology. 23 (2): e20-e30.
51. Lee D-H, et al. 2006. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes results from the National Health and Examination Survey 1999–2002. Diabetes care. 29 (7): 1638-1644.
52. Li D, et al. 2007. Platelet phospholipid omega−3 PUFA negatively associated with plasma homocysteine in middle-aged and geriatric hyperlipaemia patients. Prostaglandins, leukotrienes and essential fatty acids. 76 (5): 293-297.
53. McDowell IF & Lang D 2000. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. The journal of nutrition. 130 (2): 369S-372S.
54. Piolot A, et al. 2003. Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health. Journal of laboratory and clinical medicine. 141 (1): 41-49.
55. Roche H & Gibney M 1996. Postprandial triacylglycerolaemia: the effect of low-fat dietary treatment with and without fish oil supplementation. European journal of clinical nutrition. 50 (9): 617-624.
56. Sachdev P 2004. Homocysteine, cerebrovascular disease and brain atrophy. Journal of the neurological sciences. 226 (1): 25-29.
57. Saedisomeolia A, Wood LG, Garg ML, Gibson PG & Wark PA 2009. Lycopene enrichment of cultured airway epithelial cells decreases the inflammation induced by rhinovirus infection and lipopolysaccharide. The Journal of nutritional biochemistry. 20 (8): 577-585.
58. Schiano V, et al. 2008. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clinical nutrition. 27 (2): 241-247.
59. Schmidt S, et al. 2012. Regulation of lipid metabolism-related gene expression in whole blood cells of normo-and dyslipidemic men after fish oil supplementation. Lipids health Disease. 11: 172.
60. Selhub J 1999. Homocysteine metabolism. Annual review of nutrition. 19 (1): 217-246.
61. Smulders YM & Blom HJ 2011. The homocysteine controversy. Journal of inherited metabolic disease. 34 (1): 93-99.
62. Stamler JS, et al. 1993. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. Journal of clinical investigation. 91 (1): 308.
63. Taouis M, et al. 2002. N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. American journal of physiology-endocrinology and metabolism. 282 (3): E664-E671.
64. Tayebi-Khosroshahi H, et al. 2013. Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients. Iranian journal of kidney diseases. 7 (6): 479-484.
65. Vessby B 2000. Dietary fat and insulin action in humans. British journal of nutrition. 83 (S1): S91-S96.
66. Weiss N, et al. 2003. Influence of hyperhomocysteinemia on the cellular redox state–impact on homocysteine-induced endothelial dysfunction. Clinical chemistry and laboratory medicine. 41 (11): 1455-1461.
67. West S, et al. 2005. Acute effects of monounsaturated fatty acids with and without omega-3 fatty acids on vascular reactivity in individuals with type 2 diabetes. Diabetologia. 48 (1): 113-122.
68. WHO 2011. Global status report on noncommunicable diseases 2010. WHO: Geneva.
69. Yokoyama M, et al. 2007. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. The lancet. 369 (9567): 1090-1098.
70. Zeman M, et al. 2006. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin–fibrate combination. The journal of nutritional biochemistry. 17 (6): 379-384.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
